To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCAPI1479 | Efavirenz |
Efavirenz is a nonnucleoside HIV-1 reverse transcriptase (RT) inhibitor which selectively inhibits the glucuronidation of 3'-Azido-3'-deoxythymidine β-D-glucuronide, Sodium Salt. Studies suggest that Efavirenz binds to a distinct site of reverse transcrip
More description
|
|
| DC8897 | Delavirdine |
Delavirdine(U 90152) is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).
More description
|
|
| DC11352 | Delavirdine (mesylate) |
Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that selectively inhibits HIV-1 reverse transcriptase over DNA polymerase α and δ in vitro (IC50s = 0.26, 440, and >550 μM, respectively).
More description
|
|
| DC7007 | BMS-538203 |
BMS-538203 is a highly efficient HIV integrase inhibitor and antiviral agent.
More description
|
|
| DC9480 | Atazanavir (sulfate) |
Atazanavir sulfate is a sulfate salt form of atazanavir that is an highly potent HIV-1 protease inhibitor.
More description
|
|
| DC9029 | Abacavir |
Abacavir is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.
More description
|
|
| DC11806 | MK-0536 |
A potent HIV-1 integrase strand transfer inhibitor with IC50 of 33 nM, 9.5 nM, 40 nM, 20 nM and 237 nM for wt IN, IN Y143R, IN N155H, G118R and IN G140S-Q148H, respectively.
More description
|
|
| DC11807 | HIV InSTI-1 |
A potent HIV integrase strand transfer inhibitor (InSTIs) with IC50 of 8 nM in HIV replication assay.
More description
|
|
| DC11854 | IDX899 |
A novel potent, selective HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with EC50 of 1, 1.3, 2.8 and 11 nM for WT, K103N, Y181C and K103N/Y181C, respectively.
More description
|
|
| DC11628 | HIV-1 Integrase Inhibitor 1 |
A novel compound that disrupts the HIV-1 integrase LEDGF interaction.
More description
|
|